A clinical study on Huangqi Oral Solution in treatment of vascular inflammation in patients with chronic heart failure-myocardial fibrosis
Lyu Zhongying
Zhu Xinhua
Li Hongjian.
Abstract：Objective To discuss the effect of Huangqi Oral Solution in improvement of vascular inflammation in patients with chronic heart failure (CHF)-myocardial fibrosis. Methods The patients (n=90) were chosen from Department of Hypertension of the Fifth Affiliated Hospital of Xinjiang Medical University, and the divided into control group and observation group (each n=45). All 2 groups were given cardiotonic, diuretic, dilatation and anti-hypertension treatment, and observation group was given Huangqi Oral Solution at the same time. The changes of left ventricular ejection fraction (LVEF), serum brain natriuretic peptide (BNP), 6-minute walk distance (6MWD), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high sensitivity C-reactive protein (hs-CRP) were observed and recorded in 2 groups, and improvement effect on heart function was compared between 2 groups. Results After treatment, LVEF, BNP, 6MWD, IL-6, TNF-α and hs-CRP were all improved in 2 groups and the improvement was more significant in observation group. The total effective rate of heart function improvement was 93.3% in observation group and 71.1% in control group, and the difference between 2 groups had statistical significance. Conclusion Huangqi Oral Solution can improve heart function and relieve vascular inflammation in patients with CHF-myocardial fibrosis.
Keywords：Huangqi Oral SolutionChronic heart failureMyocardial fibrosisVascular inflammation
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 1089-1091 )